DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
CC-223 is an investigational drug.
There have been 5 clinical trials for CC-223. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, and Lymphoma. The leading clinical trial sponsors are Celgene Corporation and [disabled in preview].
There are thirty-four US patents protecting this investigational drug and three hundred and forty-four international patents.
Recent Clinical Trials for CC-223
|Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma||Celgene Corporation||Phase 1|
|CC-223 and Ketoconazole Drug-Drug Interaction Study||Celgene Corporation||Phase 1|
|A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects||Celgene Corporation||Phase 1|
Top disease conditions for CC-223
Top clinical trial sponsors for CC-223
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CC-223||Start Trial||Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines||Signal Pharmaceuticals, LLC (San Diego, CA)||Start Trial|
|CC-223||Start Trial||Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3- ,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use||Signal Pharmaceuticals, LLC (San Diego, CA)||Start Trial|
|CC-223||Start Trial||Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors||Signal Pharmaceuticals, LLC (San Diego, CA)||Start Trial|
|CC-223||Start Trial||Treatment of cancer with dihydropyrazino-pyrazines||Signal Pharmaceuticals, LLC (San Diego, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CC-223||European Patent Office||3131552||2034-04-16||Start Trial|
|CC-223||New Zealand||629860||2034-04-16||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|